COMPANY PROFILE

Enterin

Philadelphia-based biotechnology company improving the quality of life of patients with neurodegenerative conditions by repairing the gut-brain axis

Philadelphia, United StatesFounded 2016Biotech & Life Sciences

Valuation $50–100M Last recorded · 2023

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Enterin

Enterin Inc. is a pioneering biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases by targeting the gut-brain axis. The company operates in the healthcare and pharmaceutical market, primarily serving patients with conditions such as Parkinson's Disease. Enterin's business model revolves around the research and development of novel drugs, with its lead compound, ENT-01, currently in Phase 2B clinical trials. The company generates revenue through the development and potential commercialization of its proprietary treatments. By restoring normal signaling between the gut and the brain, Enterin aims to significantly improve the quality of life for patients suffering from neurodegenerative diseases.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Philadelphia, United States
Employees: 16
Open positions: None listed
Dealroom signal: 73.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES DOther financing	Dec 2023	$5.1M	$71M	Undisclosed	↗
CONVERTIBLEOther financing	Oct 2022	$6M	—	Undisclosed	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Enterin website traffic

Latest recorded traffic for Enterin is 400 monthly website visits, down 81.8% over the last three months. Enterin's team declined 5.9% over the past year.

Latest monthly visits400 3-month web change-81.8% 1-year team growth-5.9%

Monthly website visitsJan 2017–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational
ELElectroCoreHelping patients across the globe who suffer from pain and chronic conditions by harnessing the power of nVNS, innovation, and technology to develop safe and clinically backed treatments	Rockaway Township, United States	Operational
ACAccexibleDeveloping a speech analysis platform based on AI models to early detect diseases as dementia, Parkinson, and coronary disease	Bilbao, Spain	Operational
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
SCScribensDevelopment of non-invasive tools for early detection and follow-up of neurological dysfunctions	Montreal, Canada	Closed
IXIxakaCell and gene therapies treating serious diseases	London, United Kingdom	Operational
WAWaveBreakSmall-molecule therapeutics for neurodegenerative diseases	Cambridge, United Kingdom	Operational